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QSARAbstract The multicomponent syntheses of 2,4-di-aryl-quinolines and analogous polycyclic
derivatives as anti-tuberculosis agents were described. They were prepared via Beyer and Friedla¨n-
der methods under microwave irradiation in short reaction times and good yields. Several homoge-
neous and heterogeneous acid catalysts were compared for preparing 2,4-di-arylquinolines and
among them trifluoroacetic acid (TFA) reached the higher yields. Two derivatives exhibited activity
against Mycobacterium tuberculosis H37Rv (Mtb), underwent additional testing and were consid-
ered lead compounds. The synthesis of a series of polycyclic analogous led to six new active com-
pounds and a Quantitative Structure Activity Relationship study (QSAR) study was established.
 2018 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) is caused by bacteria (Mycobacterium tuber-
culosis) that most often affect the lungs. In 2016, an estimated
1 million children became ill with TB and 250,000 children died
of TB (including children with HIV associated TB). Multidrug-
resistant TB (MDR-TB) remains a public health crisis and a
health security threat. WHO estimates that there were
600,000 new cases with resistance to rifampicin, the most effec-
tive first-line drug, of which 490,000 had MDR-TB. Ending the
TB epidemic by 2030 is among the health targets of the newly
adopted Sustainable Development Goals. By June 2017, 89
Fig. 2 Lead fused quinolines A-C.
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introduced delamanid (a dihydro-nitroimidazooxazole deriva-
tive), in an effort to improve the effectiveness of MDR-TB
treatment regimens (Tuberculosis Fact sheet, WHO, 2018).
Bedaquiline, previously known as TMC207 (Fig. 1), was
developed by Johnson & Johnson pharmaceutical company.
This diarylquinoline (DARQ) acts by a novel mechanism by
targeting proton pump of adenosine triphosphate (ATP) syn-
thesis, leading to inadequate synthesis of ATP (Andries
et al., 2005; Rustomjee et al., 2008). A quinoline moiety is its
essential pharmacophoric feature and the bedaquiline perfor-
mance encouraged several authors for the design and synthesis
of new drugs (Tanwar et al., 2016). The quinoline alkaloids 4-
methoxy-2-phenylquinoline, graveolinine and kokusagine iso-
lated from Lunasia amara, showed significant activity towards
M. tuberculosis H37Rv in vitro (Metallidis et al., 2007). More
recently, new 4-substituted quinoline derivatives of the anti-
malarial drug mefloquine exhibited anti-tuberculosis properties
(Eswaran et al., 2010). Furthermore 2-substituted quinolines
isolated from plants or prepared by synthesis, have exhibited
activity against leishmaniasis (Fournet et al., 1996; Gopinath
et al., 2014), Chagas disease (Muscia et al., 2011) andM. tuber-
culosis (Jain et al., 2003; Patel et al. 2014, 2015). The quinoline
ring was shown to confer anti-TB activity and confirms that
quinoline-based scaffolds are promising leads for new TB drug
developments (Casal and Ası´s, 2017) as depicted in Fig. 2 for
our previously synthesized quinolines A-C (Muscia et al.,
2014). We have also reported the microwave-assisted Do¨bner
synthesis of 2-phenylquinoline-4-carboxylic acids and their
activities against malaria, trypanosomiasis and leishmaniasis
(Muscia et al., 2008). The parent compound 2-phenyl-4-
quinolincarboxylic acid 4 (Atophan) and its analogous 5, 6,
7 and 8, were further evaluated for growth inhibitory activity
towards M. tuberculosis H37Rv (Mtb) through the National
Institute of Allergy and Infectious Diseases (NIAID,
USA) and showed no activity (Scheme 1, A). Since 2-
styrylquinoline-4-carboxylic acids had not been sufficiently
explored as anti-TB agents and thus the effect of a vinyl
group, we have synthesized a series of ten derivatives. Only
the compounds featuring the 3,5-di-OCH3-phenyl, 3,4-
methylendioxyphenyl and 1-naphthyl moieties attached at
the C2 of vinyl group showed weak activity against M. tuber-
culosis under aerobic conditions (Muscia et al., 2017). Thus the
analogous 2-aryl-4-quinolin-carboxylic acids 9–11 and 14 were
prepared (Scheme 1, A and B). Although these four derivatives
had been already reported, their NMR spectra were not
described. Moreover, compound 9 with a 1-naphthyl ring
attached at C2 was cited for the treatment of TB (TsatsasFig. 1 Chemical structure of bedaquiline.et al., 1955) but these data are not available. Later, the family
of DARQ 16–23 was prepared via the Beyer method, another
multicomponent reaction (MCR), with the aim to analyze the
effect of introducing a second aryl moiety at C4 of the quino-
line ring (Scheme 2).
Finally, the DARQ series was extended to the polycyclic
and fused quinolines 26–45 analogous to our lead compounds
(Schemes 3 and 4). A computational analysis of the different
molecular descriptors for each product was performed in order
to establish a Quantitative Structure Activity Relationship
(QSAR) study.
2. Results and discussion
2.1. Chemistry
The microwave-assisted Do¨bner reaction from substituted ani-
lines (1), arylaldehydes (2) and pyruvic acid (3) was employed
to prepare 2-aryl-4-quinoline carboxylic acids 9–11, (Scheme 1,
A) (Muscia et al., 2008). Although the yields of this MCR are
poor, it is worthy to use in order to achieve in short reaction
times a wide variety of substituted quinolines from easily
affordable starting materials. Furthermore, this work showed
that microwave irradiation (MW) improved all yields com-
pared to two-hour thermal heating. To complete this first ser-
ies, the Pfitzinger reaction (Pfitzinger, 1886) from isatine (12)
and 3-acetyl-phenanthrene (13) was used to afford compound
14 (Scheme 1, B).
In order to determine the effect on the anti-TB activity of a
second aryl moiety attached at position 4 of the quinoline, the
pyruvic acid of Do¨bner synthesis was replaced for a variety of
methyl aryl ketones (15) maintaining the same neat reaction
conditions (Scheme 2). Therefore, 2,4-diarylquinolines 16–23
were obtained via the microwave assisted one-pot Beyer
method (Beyer, 1886), as a modification of the Do¨bner-
Miller reaction. Owing to the low yields, the addition of homo-
geneous catalysts, trifluoroacetic acid (TFA) and Eaton´s
reagent (Eaton et al., 1973), and heterogeneous catalysts (sul-
famic acid (H2NSO3H) and Amberlyst 15) was evaluated.
The reaction times and yields for compounds 16–23 are shown
in Table 1. TFA catalysis proved to be more effective as long
as the yields were between 35 and 89% and the reactions times
were within 1.5–9 min. Whereas for compounds 21 and 22,
Eaton´s reagent and no catalyst, respectively, exhibited the best
performances.
A variety of synthetic methods have been developed to
obtain 2,4-disubstituted quinolines. In this regard, 2,4-
diarylquinolines were prepared by reactions of o-isocyano-b-
methoxystyrenes with nucleophiles, from 2-iodoanilines and
alkynyl aryl ketones, Silver-catalyzed cascade reaction of o-
aminoaryl compounds with alkynes, among others. The syn-
thesis of compounds 16 (Tanwar et al., 2016; Kobayashi
Scheme 1 Synthesis of 2-aryl-4-quinolincarboxylic acids 4–11 and 14 via Do¨bner and Pfitzinger reactions.
Scheme 2 Synthesis of 2,4-DARQ 16–23 via Beyer method.
934 G.C. Muscia et al.et al., 2004; Prasad Korivi and Cheng, 2006; Tang et al., 2011;
Li et al., 2011; Zhang et al., 2013; Xu et al., 2016), 17 (Ahmad
et al., 2012), 19 (Kobayashi et al., 2004; Tang et al., 2011;
Palimkar et al., 2003; Rehan et al., 2015; Muscia et al.,
2006), 21 (Tang et al., 2011; Zhang et al., 2013; Enugala
et al., 2008) and 22 (Xu et al., 2016; Rehan et al., 2015) were
reported by these or other two-steps methods involving long
reaction times and expensive reagents or by MCR with high-
priced catalysts. Recently, compounds 16, 19 and 22 wereobtained in comparable yields to our work, via MW-assisted
Povarov reaction in the presence of p-sulfonic acid calix[4]
arene (CX4SO3H) as catalyst (Liberto et al., 2017). The synthe-
sis of compound 18 was found as a progress report from the
reaction of 2-vinylaniline and piperonal after 15 h in refluxing
toluene and 40% yield, and its melting point and NMR spectra
were not given (Walter, 1998). Compounds 20 and 23 have not
been previously described. The last one possesses a 4-sulfona
mido-5-methylisoxazol-3-yl substituent at C6 position and
Scheme 3
Synthesis, anti-tuberculosis activity and QSAR study 935was prepared from sulfamethoxazole, a recognized antimicro-
bial agent and thus a pharmacophore moiety for anti-TB activ-
ity (Aly, Abadi, 2004).The above described experimental conditions support that
the MW-assisted Beyer method for the synthesis of 2,4-
diarylquinolines promoted by TFA is a rapid, neat and versa-
Scheme 4 Synthesis of quinoline derivatives 44 and 45 via Beyer method.
Table 1 Preparation of compounds 16–23 with acid catalysts.
Compd No Catalyst TFA Eaton´s H2NSO3H Amberlyst 15
Time
(min)
Yield
(%)
Time
(min)
Yield
(%)
Time
(min)
Yield
(%)
Time
(min)
Rto
(%)
Time
(min)
Yield
(%)
16 6 63 9 89 10 43 6 19 5 19
17 20 30 3 56 3 13 4 50 nr –
18 6 <10 2.5 44 1 26 2 24 5 <10
19 3 49 1.5 76 14 35 3 49 3 13
20 4 18 5 52 2 24 4 27 2 <10
21 10 13 5 12 6 37 6 32 1 11
22 6.5 38 2 <10 2 30 2 <10 2 <10
23 6 <10 4 35 3 20 2 <10 2 <10
936 G.C. Muscia et al.tile reaction that can be extended to a large variety of 2,4-
diarylquinolines successfully prepared in short times.
Taking into account the remarkable anti-TB activity results
for compounds 14 and 18 (Section 2.2.1) and considering our
former lead fused quinolines A-C (Fig. 2), the analogous 26–
43 were synthesized employing MW-assisted Friedla¨nder reac-
tion (Scheme 3) (Muscia et al., 2014) and 44–45 through the
Beyer method (Scheme 4), both under TFA catalysis.
The tetrahydroacridine derivative 26 was prepared in 2015
using a tandem process that involves in situ aerial oxidation of
the corresponding alcohol followed by Friedla¨nder annulation
in the presence of KOH at 80 C for 7 h (Anand et al., 2015).
Recently was reported the water mediated green Friedla¨nder
synthesis of the polycyclic quinolines 28–32 and 34 under
diluted HCl catalysis at room temperature. Although the
authors obtained comparable yields to ours, the reactions pro-
ceeded in longer reaction times (Gopi and Sarveswari (2017)).
Finally the 4-indolylquinoline derivative 44 was cited by Chen
et al. in 2015 in a process that involves two steps, the Michael
addition of indole to a nitrochalcone followed by a reductive
cyclization of the indolylnitrochalcone intermediate.
The spectroscopical analysis of our products agrees with
the reported data. All our synthesized quinoline derivatives
were obtained in short reaction times under eco-friendly condi-
tions, ease of purification and the ready availability of the
starting materials. These advantages are imperative for design-
ing biological active compounds.2.2. Biological activity
2.2.1. In vitro activity against M. Tuberculosis
Initially the 2-aryl-4-quinoline carboxylic acids 9–11, 14 and
DARQ 16–23 were evaluated for growth inhibitory activity
towards M. tuberculosis H37Rv (Mtb) through the National
Institute of Allergy and Infectious Diseases (NIAID, USA)
and rifampicin was used as reference drug (NIH/NIAID Task
Order A01 Contract HHSN272201100012I).
Compounds 14, 18 and 19 exhibited IC50 values of 60.25, 29
and 19 mM, respectively but only compounds 14 (2-
phenanthren-3-yl) and 18 2-(3,4-methylenedioxyphenyl)
underwent additional testing and are also considered lead com-
pounds. This subset was determined by an algorithm that con-
sidered primarily activity and analytical quality of the samples
but also considered other aspects such as chemotype series and
solubility. This testing includes in vitro evaluation of H37Rv
under both anaerobic and aerobic conditions as well as mini-
mal bactericidal concentration (MBC). Single drug resistant
strain testing (isoniazid, rifampicin and ofloxacin resistant
Mtb strains) and intracellular inhibition ofMtb H37Rv growth
using murine macrophage cell line and cytotoxicity in this cell-
line were also determined.
The twenty derivatives 26–45 designed as analogous of lead
compounds A-C, 14 and 18 (Schemes 3 and 4) were evaluated
against Mtb using rifampicin as reference drug (MIC
0.0072 mM) and six of them showed inhibitory activity
Synthesis, anti-tuberculosis activity and QSAR study 937(Table 2). The additional halogen atom (Cl or F) attached at
C2 of the 4-phenyl moiety in compounds 26–29 did not
improve the IC50 values of A-C. The chlorine atom at C6 of
quinoline ring in compound 38 conferred less activity mean-
while the trifluormethyl group increased the activity compar-
ing to the lead 18 however it was not selected for additional
testing. The polycyclic quinolines 35–37 as constrained models
of 18 lacked of activity as well as the 2-phenanthryl derivatives
42 and 43 analogous to 14 (Fig. 3).
2.2.2. Minimal inhibitory concentration (MIC)
The MIC for each compound was determined by testing ten,
two-fold dilutions in concentration ranges. The MIC is
reported as the lowest concentration (mM) of drug that visuallyTable 2 In vitro activity against M. tuberculosis H37Rv of analogo
Compd Structure
26
27
28
29
38
45inhibited growth of the organism. In addition, the percentage
of inhibition at the MIC is provided for compound 14
(Table 3). Rifampicin and isoniazid were used as positive con-
trols. Although MIC values of compound 14 were higher than
the MIC values for the reference drugs, this compound showed
a similar percent inhibition value against the rifampicin resis-
tant strain (RMP-R) and a higher percent inhibition value
against the ofloxacin resistant strain (OFX-R). On the other
hand, compound 18 had limited activity against M. tuberculo-
sis resistant.
2.2.3. Minimal bactericidal concentration (MBC)
The established rejection value of >40 colonies for the MBC
assay was based on the calculated concentration of Mtb inus active compounds.
IC50 (mM) IC90 (mM) MIC (mM)
81 158 >200
65 97 102
130 190 200
95 >200 >200
162 >200 >200
21 118 73
Fig. 3 SAR of the synthesized quinolines.
938 G.C. Muscia et al.the MIC plates. Results are determined based on Colony
Forming Units (CFUs) enumerated from agar plates. Only
agar plates with countable colonies have reportable counts.
If a compound lacks bactericidal activity, many times the
CFUs are too numerous to count (TNTC) and are thus
reported as such. This result was the one obtained for com-
pound 14, meanwhile compound 18 proved bactericidal activ-
ity so far the MBC value was 100 mM.
2.2.4. Low-oxygen recovery assay (LORA)
Traditional screening of drugs against M. tuberculosis only
addresses or targets the organism in an active replicating state.
It is well documented that Mtb can reside in a state of non-
replicating persistence (NRP) which has not been adequately
assessed in the development of new antimicrobials. Results
for the LORA assay are reported as the lowest concentration
of drug that visually inhibited growth of the organism. This
NRP state is considered an antimicrobial tolerance factor, so
LORA may identify drugs that could reduce anti-tubercular
treatment period. Compound 14 exhibited higher MIC value
under anaerobic than under aerobic conditions. Compound
18 had activity against M. tuberculosis under low oxygen con-
ditions and the MIC, IC50 and IC90 values were 136, 7.3 and
30 mM, respectively.Table 3 Percentage of inhibition at the MIC for compound 14.
Comp MIC
H37Rv
(mM)
%
Inhiba
MBC
H37Rv
(mM)
MIC
INH-Rb
(mM)
14 25.1 60 NAe 12.6
Rifampicin
(pos control)
0.06 57 0.95 0.06
Isoniazid
(pos control)
NA NA NA NA
a Percent inhibition at the MIC concentration.
b INH-R: Isoniazid Resistance.
c RMP-R: Rifampicin Resistance.
d OFX-R: Ofloxacin Resistance.
e NA: Not Applicable, Colony Counts above the established rejection
f NA: Not Applicable, Compound not used in assay.2.2.5. Intracellular drug activity
Intracellular drug activity is reported as log reduction values
calculated as reduction in Mtb concentration from zero hour
to 7 days post-infection. The three concentrations chosen were
based on the MIC data generated in the HTS primary screen.
The mid concentration bracketed the reported MIC with the
lower concentration ten-fold below the mid and the higher
concentration tenfold above the mid. Drug cytotoxicity is
reported as cell proliferation, macrophage toxicity (MTT) or
percentage of viability. Compound 14 showed a similar ten-
dency as rifampicin, so at higher drug concentrations lower
UFC are obtained and the log reduction is higher (Table 4).
Concerning cytotoxicity, compound 14 exhibited percentages
of viability comparable to rifampicin at low and mid concen-
trations, so it is not toxic to macrophages. Compound 18
had intracellular activity againstM. tuberculosis and was cyto-
toxic (IC50 = 82 mM).
2.3. QSAR study
The analogous compounds 26–29, 38 and 45 have been classi-
fied as ’active’ and the remaining structures as ’inactive’. All
the active molecules have pIC50 values above 4.22 log units.
The molecules were built with ChemAxon Marvin Sketch 6.0
and exported to MOL2 format. A total of 1444 1D and 2D dif-
ferent molecular descriptors were calculated using PaDEL-
Descriptor v2.7, Table 5 (Todeschini and Consonni, 2009).
Descriptors with zero standard deviation in their values were
then removed. The principal component analysis (PCA)
showed that three principal components (PC) explained 97%
of the variance in the chemical structure. The first three PCA
vectors were added to the study table containing the binary
representation of the activity of the molecules (Tables 6 and
7). Summarizing, PC1 is related to the number of aromatic
bonds, PC2 with the effect and position of the substituents
and PC3 with the molecular distances between atoms and
the tertiary quinoline nitrogen.
3. Conclusion
We herein describe the multicomponent, eco-friendly synthe-
sis of 31 quinoline derivatives in short reaction times and%
Inhib
MIC
RMP-Rc
(mM)
%
Inhib
MIC
OFX-Rd
(mM)
%
Inhib
50 25.1 62 6.28 77
68 NAf NA 0.47 63
NA 0.15 74 NA NA
value of 40.
Table 4 Macrophage toxicity (MTT) and percentage of viability of compound 14.
Comp. Macrophage
log reduction
(low conc)
Macrophage
log reduction
(mid conc)
Macrophage log reduction
(high conc)
MTT
% viability
(low conc)
MTT
% viability
(mid conc)
MTT
% viability
(high conc)
14 1.56 1.98 2.54 100 100 80
Rifampicin 0.58 2.00 2.98 90 79 82
Table 5 Calculated molecular descriptors for compounds 26–45.
Compd AMR nHBAcc nHBDon nRing nRotB Ro5 Failures TPSA MW XLogP
26 26.37 1 0 4 1 1 12.89 327.058 6.380
27 29.28 1 0 4 1 1 12.89 341.073 6.949
28 21.62 1 0 4 1 1 12.89 311.087 6.243
29 24.54 1 0 4 1 1 12.89 325.103 6.812
30 23.3 3 0 6 1 1 31.35 405.032 6.098
31 21.14 5 0 4 2 1 73.10 318.100 5.846
32 39.5 2 0 4 1 1 29.96 369.068 6.210
33 23.74 2 0 4 1 0 29.96 325.066 4.959
34 3.89 4 0 6 3 1 56.03 426.136 12.668
35 11.36 6 0 5 3 1 74.49 370.095 7.322
36 16.97 6 0 5 3 1 74.49 404.056 6.363
37 22.87 2 0 4 1 1 29.96 307.076 6.055
38 13.08 3 0 5 2 1 31.35 359.071 7.531
39 18.7 3 0 5 2 1 31.35 393.032 6.572
40 5.615 1 0 6 2 1 12.89 415.112 12.877
41 28.48 2 0 4 1 1 29.96 341.037 5.096
42 17.68 3 0 6 1 1 31.35 371.071 7.057
43 10.77 4 1 6 2 1 47.14 364.121 6.034
44 13.96 3 0 5 2 1 31.35 377.061 6.435
45 13.9 3 0 5 3 1 31.35 393.097 8.549
Table 6 Eigenvectors for the first components.
Principal Component VR2Dta nBondsMb nAtomPc MDEC-23d nssCH2e nwHBaf C2SP2g
PC1 0.1087 0.5011 0.456 0.5194 0.1219 0.3972 0.2942
PC2 0.9873 0.0316 0.0092 0.1446 0.0257 0.0413 0.0246
PC3 0.1108 0.0458 0.5291 0.7276 0.3088 0.0126 0.2825
Major contribution property values to each PC are depicted in bold.
a Normalized Randic-like eigenvector-based index from detour matrix.
b Total number of bonds that have bond order greater than one.
c Number of atoms in the largest pi system.
d Molecular distance edge between all secondary and tertiary nitrogens.
e Count of atom-type E-State: ACH2A.
f Minimum E-States for weak Hydrogen Bond acceptors.
g Doubly bound carbon bound to two other carbons.
Synthesis, anti-tuberculosis activity and QSAR study 939from easily affordable starting materials and their anti-TB
activity. Among the synthesized compounds, fifteen are
novel structures and the remaining terms have been reported
in the literature although prepared by other experimental
conditions and from different expensive starting materials.
All products were evaluated in vitro against M. tuberculosis
(Mtb) H37Rv. Nine compounds showed inhibitory activity
and compounds 14 and 18 underwent additional testing.
Compound 18 had limited activity against M. tuberculosis
resistant, proved to be bactericidal and had activity against
M. tuberculosis under low oxygen conditions, although wascytotoxic. By contrast, compound 14 had a higher percent
inhibition value against the ofloxacin resistant strain
(OFX-R), lacked of bactericidal activity, was not active
under low oxygen conditions and exhibited percentages of
viability comparable to rifampicin at low and mid concen-
trations, so it was not toxic to macrophages. Considering
the established minimal structural requirements supported
by theoretical calculations, it is worthy to note that the
introduction of a sulfonamide moiety at C6 of the quinoline
ring in future series could improve the anti-TB activity and
diminish the cytotoxicity.
Table 7 Principal components for each tested compound.
Compound PC1 PC2 PC3
26 11.534 3.415 1.432
27 10.755 3.2 2.983
28 11.534 3.415 1.432
29 10.755 3.2 2.983
30 4.005 1.841 1.331
31 7.314 0.285 1.867
32 9.959 1.55 1.858
33 9.305 2.506 0.313
34 24.349 4.6 1.443
35 4.53 2.449 4.007
36 5.31 1.178 3.073
37 7.459 15.38 1.526
38 2.649 2.554 2.386
39 3.433 1.112 1.447
40 22.488 4.523 3.086
41 9.305 2.506 0.313
42 4.483 2.426 1.824
43 10.869 14.144 0.758
44 3.433 1.112 1.447
45 2.368 2.408 2.087
940 G.C. Muscia et al.4. Experimental section
4.1. Chemistry
The structures of the synthesized compounds were established
through their 1H and 13C NMR, MS and IR spectra. Melting
points were determined in a capillary Electrothermal 9100
SERIES-Digital apparatus and are uncorrected. 1H and 13C
NMR spectra were recorded at room temperature using a Bru-
ker 300 spectrometer. The operating frequencies for protons
and carbons were 300.13 and 75.46 MHz, respectively. When
indicated, the spectra were obtained using a Bruker 600 spec-
trometer. The operating frequencies for protons and carbons
were 600 and 151 MHz, respectively. The chemical shifts (d)
were given in ppm. IR spectra were recorded on an FT Perkin
Elmer Spectrum One from KBr discs. Mass spectra were mea-
sured on MS/DSQ II Thermo Scientific DIP or Agilent MSD,
electrospray ionization, positive ion. Elemental analysis (C, H
and N) were performed on an Exeter CE 440 and the results
were within ±0.4% of the calculated values. Analytical TLCs
were performed on DC-Alufolien Kieselgel 60 F254 Merck.
Microwave-assisted reactions were carried out in a CEM Dis-
cover oven.
4.1.1. 2-Arylquinoline-4-carboxylic acids
4.1.1.1. General procedure for compounds 9–11. A mixture of
the corresponding aniline (0.37 mL, 4.1 mmoles), arylaldehyde
(0.58–0.73 g, 3.9 mmoles) and pyruvic acid (0.30 mL,
4.3 mmoles) placed in a 50 mL round-bottomed flask was sub-
jected to MW irradiation at 400 W and 250 C. After comple-
tion of the reaction (TLC), the reaction mixture was allowed to
cool and the residual semisolid crystallized. When this did not
occur, the reaction mixture was diluted with CH2Cl2 (15 mL)
and washed with water, 5% HCl (10 mL) and brine (10 mL).
This was then dried (Na2SO4) and concentrated in vacuo to
give a solid product (Muscia et al., 2008).4.1.1.2. 2-(3,4-methylenedioxyphenyl)quinoline-4-carboxylic
acid 9. White solid; yield 45%, mp 215–218 C, crystallized
from EtOH. 1H NMR (DMSO d6): d 6.13 (s, 2H, OCH2O),
7.08 (d, J = 8.1 Hz, 1H, H-Ph), 7.66 (1H, t, Het-H), 7.79–
7.85 (2H, m, Ph-H and Het-H), 7.87 (1H, s, Ph-H), 8.11
(1H, d, J = 8.5 Hz, Het-H), 8.39 (1H, s, Het-H), 8.59 (1H,
d, J = 8.5 Hz, Het-H). 13C NMR (DMSO d6): d 101.63
(OCH2O), 107.05, 108.68, 118.81, 121.84, 123.29, 125.33,
127.40, 129.64, 130.19, 132.24, 137.63, 148.26, 149.08, 155.21
(Carom), 167.7 (COOH). 101.6, 107.0, 108.6, 118.8, 121.8,
123.2, 125.3, 127.4, 129.6, 130.1, 132.2, 137.6, 148.2, 149.0,
155.2, 167.7. IR (cm1): t 3392, 3004, 1715, 1264, 1036, 764,
690. MSD 292 (M+).
Anal. Calcd. for C17H11NO4: C, 69.62; H, 3.78; N, 4.78.
Found: C, 69.58; H, 3.72; N, 4.81.
4.1.1.3. 2-(naphthalen-1-yl)quinoline-4-carboxylic acid 10. Pale
yellow solid; yield 25%, mp 170 C d, Lit. 198 C (Buu-Hoı¨,
1943), crystallized from cyclohexane. 1H NMR (DMSO d6):
d 7.46–7.47 (2H,m, Ph-H), 7.61 (1H, t, Het-H), 7.66 (1H, t,
Ph-H), 7.71 (1H, t, Het-H), 7.83–7.87 (2H, m, Ph-H), 7.93
(1H, d, J = 8.2 Hz, Ph-H), 8.13 (1H, d, J = 7.9 Hz, Ph-H),
8.20 (1H, s, Het-H), 8.25 (1H, d, J = 7.7 Hz , Het-H), 8.51
(1H, d, J = 7.7 Hz, Het-H). 13C NMR (DMSO d6): d 122.9,
125.2, 125.3, 125.5, 125.8, 126.6, 126.7, 127.1, 127.9, 130.0,
130.8, 131.0, 134.5, 143.6, 149.3, 157.7(Carom), 171.2 (COOH).
IR (cm1): t 3314, 3044, 1678, 1397, 779, 719. MS (EI): MSD
297 (M+).
Anal. Calcd. for C20H13NO2: C, 80.25; H, 4.38; N, 4.68.
Found: C, 80.21; H, 4.44; N, 4.60.
4.1.1.4. 2-(6-methoxynaphthalen-2-yl)quinoline-4-carboxylic
acid 11. Orange solid; yield 25%, mp 149–151 C, Lit. 258–
259 C (Buu-Hoı¨, 1949), crystallized from cyclohexane. 1H
NMR (DMSO d6): d 3.9 (3H, s, OCH3), 7.21–7.29 (3H, m,
Ph-H), 7.39–7.45 (3H, m, Ph-H), 7.92 (2H, t, Het-H), 8.07
(1H, d, J = 8.7 Hz, Het-H), 8.30 (1H, d, J = 8.7 Hz, Het-
H), 8.69 (1H, s, Het-H). 13C NMR (DMSO d6): d 55.3
(OCH3), 106.3, 113.8, 115.6, 119.3, 120.9, 124.2, 125.7, 127.5,
127.9, 130.3, 131.1, 131.6, 136.1, 151.6, 158.7, 159.8 (Carom),
160.5 (COOH). IR (cm1): t 3468, 3002, 1689, 1477, 1032,
758, 694. MSD 119.1 (M+).
Anal. Calcd. for C21H15NO3: C, 76.58; H, 4.59; N, 4.25.
Found: C, 76.54; H, 4.57; N, 4.28.
4.1.1.5. 2-(phenanthren-3-yl)quinoline-4-carboxylic acid 14. A
mixture of 3.4 mmoles (0.5 g) of isatine and 7.1 mmoles
(1.5 g) of 3-acetyl-phenanthrene in 20 mL 20% KOH was stir-
red at reflux temperature for 7 h. The reaction mixture was
cooled to rt and concd HCl was added to pH 6.5 and the crys-
talline solid was filtered and crystallized from i-PrOH.
White solid; yield 54%, mp 261–263 C, Lit. 268 C (Buu-
Hoı¨, 1943). 1H NMR (600 MHz, CDCl3): d 7.70–7.80 (3H,
m), 7.90–7.96 (3H, m), 8.04 (1H, d, J= 7.8 Hz), 8.19 (1H, d,
J= 8.3 Hz), 8.30 (1H, d, J= 8.3 Hz), 8.62 (2H, t), 8.83 (1H,
s), 9.13 (1H, d, J= 8.2 Hz), 9.68 (1H, s). 13C NMR
(151 MHz, CDCl3): d 120.0, 122.5, 123.8, 125.8, 126.1, 126.9,
127.6, 127.7, 128.4, 128.7, 129.1, 129.7, 130.0, 130.4, 130.5,
130.9, 132.3, 133.1, 136.4, 138.9, 148.5, 156.3 (Carom), 168.2
(COOH). IR (cm1): t 3435, 3065, 1717, 1630, 1589, 847,
717. MSD 349 (M+).
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4.1.2. Diarylquinolines (DARQ)
4.1.2.1. General procedure for compounds 16–23. A mixture of
the corresponding aniline (0.51–1.39 g, 5.5 mmoles), arylalde-
hyde (0.55–0.79 g, 5.25 mmoles), substituted acetophenone
(0.66–0.82 g, 5.5 mmoles) and 1% of catalyst placed in a
50 mL round-bottomed flask was subjected to MW irradiation
at 400 W and 250 C. After completion of the reaction (TLC),
the reaction mixture was allowed to cool. It was diluted with
CH2Cl2 (15 mL) and washed with water, 5% HCl (10 mL)
and brine (10 mL). This was then dried (Na2SO4) and concen-
trated in vacuo to give a solid product which was crystallized
from the corresponding solvent. The yields are shown in
Table 1.4.1.2.2. 2-(3,4-methylenedioxyphenyl)-4-phenylquinoline 18.
Pale yellow solid, mp 149–151 C, crystallized from cyclohex-
ane. 1H NMR (600 MHz, CDCl3): d 6.05 (2H, s), 6.87 (1H,
d, J= 6.9 Hz), 7.15 (1H, d, J= 8.0 Hz), 7.19 (1H, s), 7.20
(1H, s), 7.39 (1H, d, J= 15.5 Hz), 7.52 (2H, t), 7.60 (1H, t),
7.76 (1H, d, J= 15.5 Hz), 8.03 (2H, d, J= 8.1 Hz). 13C
NMR (151 MHz, CDCl3): d 101.6 (OCH2O), 106.7, 108.7,
120.1, 125.2, 128.4, 128.6, 129.4, 132.6, 138.4, 144.7, 148.4,
149.9 (Carom). IR (cm
1): t 3062, 2913, 1674, 1456, 1260,
804, 717. MS (EI): 325 (M+), 252 (100%), 122 (21%), 77
(26%).
Anal. Calcd. for C22H15NO2: C, 81.21; H, 4.65; N, 4.30.
Found: C, 81.23; H, 4.63; N, 4.34.
4.1.2.3. 4-(4-hydroxyphenyl)-2-phenylquinoline 20.White solid,
mp 174–175 C, crystallized from CH2Cl2. 1H NMR (CDCl3):
d 6.57–6.62 (3H, m), 6.68 (2H, d, J= 8.2 Hz), 6.69 (1H, s),
7.15 (2H, d, J= 7.9 Hz), 7.35 (1H, s), 7.42 (2H, d,
J= 8.1 Hz), 7.83 (2H, d, J= 7.9 Hz), 7.79 (2H, d,
J= 8.1 Hz). 13C NMR (CDCl3): d 116.8, 119.8, 122.5, 124.8,
125.5, 126.9, 129.8, 130.0, 131.2, 132.6, 143.7, 146.2, 147.8
(Carom), 159.8 (Carom-OH). IR (cm
1): t 3300, 3010, 1594,
1485, 1283, 834, 751, 699. MS (EI): 297 (M+), 182 (100%),
121 (36%), 93 (50%), 77 (22%).
Anal. Calcd. for C21H15NO: C, 84.82; H, 5.08; N, 4.71.
Found: C, 84.79; H, 5.10; N, 4.67.
4.1.2.4. 2,4-diphenyl-6-(4-sulfonamido-5-methylisoxazol-3-yl)
quinoline 23. White solid, mp 222–223 C, crystallized from
EtOH. 1H NMR (DMSO d6): d 2.51 (3H, s), 6.07 (1H, s),
6.59 (2H, d, J= 8.8), 7.67–7.20 (10H, m), 7.98 (2H, d,
J= 7.2 Hz), 10.94 (1H, s). 13C NMR (DMSO d6): d 12.5
(CH3), 112.1, 125.2, 127.0, 127.5, 128.5, 128.9, 129.1, 133.7,
137.1, 143.4 (Carom). IR (cm
1): t 3369, 3283, 3109, 3065,
1674, 1587, 1174, 1087, 760, 696. MS (EI): 442 (M+), 207
(100%), 162 (31%), 92 (32%), 77 (24%).
Anal. Calcd. for C25H19N3O3S: C, 68.01; H, 4.34; N, 9.52.
Found: C, 68.05; H, 4.31; N, 9.55.4.1.3. Polycyclic quinolines
4.1.3.1. General procedure for compounds 26–43. A neat mix-
ture of 1.00 mmol of 2-amino-5-chlorobenzophenones (0.23–
0.27 g) or 2-amino-5-nitrobenzophenones (0.24–0.28 g) 24
and 1.50 mmol of the corresponding cyclanone or methylke-tone (0.15–0.26 g) 25 with 0.15 mL TFA was subjected to
MW irradiation, at 400 W and 250 C. The completion of
the reaction was determined by TLC (Muscia et al., 2014).
The product was crystallized from EtOH and the reaction
times were 2–6 min.
4.1.3.2. 2-chloro-11-(2-chlorophenyl)-7,8,9,10-tetrahydro-6H-
cyclohepta[b]quinoline 27. White solid, yield 63%, mp 151–
153 C, crystallized from EtOH. 1H RMN (600 MHz, CDCl3):
d 1.56–1.72 (m, 2H, CH2), 1.87 (s, 4H, CH2), 2.58–2.70 (m, 2H,
CH2), 3.26–3.33 (m, 2H, CH2), 7.10 (s, 1H, H-Het), 7.19 (dd,
J= 1.4; J= 7.3 Hz, 1H, HAAr), 7.41–4.48 (m, 2H, HAAr),
7.56 (dd, J= 2.2; J= 8.9 Hz, 1H, HAAr) 7.60 (d,
J= 7.8 Hz, 1H, HAAr), 7.99 (d, J= 8.9 Hz, 1H, H-
Het).13C NMR (151 MHz, CDCl3): d 26.9 (CH2), 27.8
(CH2), 30.9 (CH2), 31.9 (CH2), 40.2 (CH2), 124.4, 127.1,
129.2, 129.7, 129.9, 130.4, 131.0, 131.7, 133.7, 135.2, 135.8,
141.8, 144.3, 165.1 (Carom). IR (cm
1): t 3044, 2918, 2841,
1575, 1468, 1169, 829, 757. MSD 342 (M+).
Anal. Calcd. for C20H17Cl2N: C, 70.18; H, 5.01; N, 4.09.
Found: C, 69.85; H, 4.96; N, 4.11.
4.1.3.3. 7-nitro-9-phenyl-3,4-dihydroacridin-1(2H)-one 33. Yel-
low solid; yield 35%, mp 195–197 C, crystallized from EtOH.
1H RMN (CDCl3): d 2.25–2.37 (m, CH2, 2H), 2.78 (t, CH2,
J= 6.7 Hz, 2H), 3.44 (t, CH2, J= 6.2 Hz, 2H), 7.19–7.23
(m, 2H, H-Ph), 7.54–7.59 (m, 3H, H-Ph), 8.21, (d,
J= 9.2 Hz, 1H, H-Het), 8.44 (s, 1H, H-Het), 8.53 (d,
J= 9.2 Hz, 1H, H-Het). 13C NMR (CDCl3): d 21.0 (CH2),
34.8 (CH2), 40.5 (CH2), 124.9, 125.0, 125.3, 126.8, 128.0,
128.5, 130.5, 145.6, 150.5, 153.2, 166.1 (Carom), 197.1
(C‚O). IR (cm1): t 3000, 2890, 1696, 1616, 1554, 1338,
714, 688. MSD 113.1 (M+).
Anal. Calcd. for C19H14N2O3: C, 71.69; H, 4.43; N, 8.80.
Found: C, 71.47; H, 4.50; N, 8.50.
4.1.3.4. 8-chloro-10-phenyl-11H-[1,3]dioxolo[40,50:5,6]indeno
[1,2-b]quinoline 35. Pale yellow solid; yield 55%, mp 254–
256 C, crystallized from EtOH. 1H RMN (600 MHz, CDCl3):
d 3.72 (s, 2H, CH2), 6.08 (s, 2H, OCH2O), 6.93 (s, 1H, H-Ph),
7.45 (d, J= 7.0 Hz, 2H), 7.54–7.62 (m, 5H, HAAr), 7.7 (s, 1H,
H-Het), 8.12 (d, J= 9.6 Hz, 1H, H-Het).
13C NMR (151 MHz, CDCl3): d 33.80 (CH2), 101.69
(OCH2O), 101.9, 105.5, 124.6, 126.6, 128.5, 128.9, 129.0,
129.2, 129.4, 130.4, 130.9, 134.1, 134.2, 135.8, 140.5, 142.0,
146.8, 148.1, 150.4, 161.2 (Carom). IR (cm
1): t 3000, 2900,
1566, 1468, 1331, 1259, 1037, 833, 708. MSD 372.0 (M+).
Anal. Calcd. for C23H14ClNO2: C, 74.30; H, 3.80; N, 3.77.
Found: C, 74.69; H, 3.89; N, 3.55.
4.1.3.5. 8-chloro-10-(2-chlorophenyl)-11H-[1,3]dioxolo
[40,50:5,6]indeno[1,2-b]quinoline 36. Pale yellow solid; yield
60%, mp 250–251 C, crystallized from EtOH. 1H RMN
(600 MHz, CDCl3): d 3.68 (q, 2H, CH2), 6.10 (s, 2H, OCH2O),
6.96 (s, 1H, HAAr), 7.35–7.38 (m, 2H, H-Ph), 7.48–7.54 (m,
2H, H-Ph), 7.63–7.66 (m, 2H, HAAr), 7.73 (s, 1H, H-Het),
8.15 (d, J= 8.9 Hz, 1H, H-Het). 13C NMR (151 MHz,
CDCl3): d 33.5 (CH2), 101.7 (OCH2O), 102.0, 105.6, 124.2,
126.4, 127.2, 129.6, 130.1, 130.5, 130.8, 131.2, 133.3, 134.1,
134.9, 139.3, 140.4, 146.7, 148.2, 150.5, 161.2, 165.4 (Carom).
IR (cm1): t 3062, 2925, 2847, 1755, 1471, 1428, 1170, 829,
759. MSD 406.0 (M+).
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Found: C, 67.88; H, 3.17; N, 3.38.4.1.3.6. 2-(benzo[d][1,3]dioxol-5-yl)-6-chloro-4-(2-fluo-
rophenyl)quinoline 37. Pale yellow solid; yield 50%, mp 133–
135 C, crystallized from EtOH. 1H RMN (600 MHz, CDCl3):
d 6.04 (s, 2H, OCH2O), 6.86 (d, J= 8.4 Hz, 1H, HAAr), 7.44–
7-52 (m, 3H, HAAr), 7.61–7.68 (m, 2H, HAAr), 7.81 (dd,
J= 2.3 Hz, J= 9.0 Hz, 1H, H-Ph),7.93 (d, J= 5.5 Hz, 2H,
H-Het), 8.16 (d, J= 8.7 Hz, 2H, H-Het). 13C NMR
(151 MHz, CDCl3) d 101.6, 106.7, 108.7, 120.1, 125.2, 128.4,
128.6, 129.4, 132.6, 138.4, 144.7, 148.4, 149.9 (Carom). IR
(cm1): t 3067, 2897, 2775, 1592, 1481, 1446, 1251, 1038,
873, 764. MSD 378.0 (M+).
Anal. Calcd. for C22H13ClFNO2 C, 69.94; H, 3.47; N, 3.71.
Found: C, 70.04; H, 3.50; N, 3.67.4.1.3.7. 2-(benzo[d][1,3]dioxol-5-yl)-6-chloro-4-phenylquino-
line 38. Pale yellow solid; yield 61%, mp 142–144 C, crystal-
lized from EtOH. 1H RMN (DMSO d6): d 6.12 (s, 2H,
OCH2O), 7.08 (d, J= 8.1 Hz, 1H, HAAr), 7.50–7.63 (m,
5H, HAAr), 7.73 (d, J= 2.0 Hz, 1H, H3C6OCH2O), 7.80
(dd, J= 2.1 Hz; J= 8.9 Hz; 1H, H3C6OCH2O), 7.92 (d,
J= 6.3 Hz, 2H, H-Het), 8.05 (s, 1H, H-Het), 8.13 (d,
J= 8.9 Hz, 1H, H-Het). 13C NMR (DMSO d6): d 102.0
(OCH2O), 107.8, 109.0, 119.9, 122.5, 124.3, 126.2, 129.3,
130.0, 130.8, 131.3, 132.2, 132.9, 137.3, 146.9, 148.3, 148.6,
149.4, 156.13 (Carom). IR (cm
1): t 3049, 2890, 1589, 1505,
1483, 1369, 1245, 1037, 827, 776, 700. MSD 360.0 (M+).
Anal. Calcd. for C22H14ClNO2: C, 73.44; H, 3.92; N, 3.89.
Found: C, 73.65; H, 3.89; N, 3.93.4.1.3.8. 2-(benzo[d][1,3]dioxol-5-yl)-6-chloro-4-(2-chlorophe-
nyl)quinoline 39. Pale yellow solid; yield 55%, mp 166–168 C,
crystallized from EtOH. 1H RMN (DMSO d6): d 6.14 (s, 2H,
OCH2O), 7.08 (d, J= 8.5 Hz, 1H, HAAr), 7.30 (s, 1H, H3C6-
OCH2O), 7.47–7.50 (m, 3H, HAAr), 7.72–7.82 (m, 2H,
HAAr), 7.93 (d, J= 6.3 Hz, 2H, H-Het), 8.12–8.30 (m, 2H-
Het). 13C NMR (DMSO d6): d 102.4 (OCH2O), 107.7, 109.0,
120.4, 122.6, 124.1, 126.3, 128.1, 130.2, 131.0, 131.2, 131.5,
132.2, 132.6, 132.7, 136.0, 145.8, 146.5, 148.6, 149.5, 156.2
(Carom). IR (cm
1): t 3086, 2879, 2776, 1602, 1472, 1246,
1036, 820, 759. MSD 394.0 (M+).
Anal. Calcd. for C22H13Cl2NO2: C, 67.02; H, 3.32; N, 3.55.
Found: C, 68.92; H, 3.36; N, 3.61.4.1.3.9. 2-(benzo[d][1,3]dioxol-5-yl)-6-nitro-4-phenylquinoline
40. Pale yellow solid; yield 58%, mp 195–197 C, crystallized
from EtOH. 1H NMR (DMSO d6): d 6.15 (s, 2H, OCH2O),
7.09 (d, J = 8.1 Hz, 1H, H3C6OCH2O), 7.57–7.70 (m, 5H,
H-Ph), 7.95–8.02 (m, 2H, H3C6OCH2O), 8.20 (s, 1H, H-
Het), 8.26 (d, J= 9.2 Hz, 1H, H-Het), 8.47 (d, J= 9.2 Hz,
1H, H-Het), 8.64 (s, 1H, d, H-Het). 13C NMR (CDCl3): d
102.2 (OCH2O), 108.0, 109.1, 120.5, 122.8, 123.4, 123.6,
124.3, 130.2, 131.8, 132.3, 136.8, 145.1, 148.7, 150.1, 150.7,
150.9, 158.9 (Carom). IR (cm
1): t 3082, 3049, 2901, 1592,
1506, 1484, 1339, 1038, 811, 703. MSD 371.0 (M+).
Anal. Calcd. for C22H14N2O4: C, 71.35; H, 3.81; N, 7.56.
Found: C, 71.30; H, 3.78; N, 7.60.4.1.3.10. 2-(benzo[d][1,3]dioxol-5-yl)-4-(2-chlorophenyl)-6-
nitroquinoline 41. Pale yellow solid; yield 55%, mp 259–
260 C, crystallized from EtOH. 1H NMR (600 MHz,
DMSO d6): d 6.10 (s, 2H, H24), 6.98 (d, J= 8.2 Hz, 1H,
H19), 7.46 (dd, J= 1.5 Hz, J= 7.5 Hz, 1H, H12), 7.51 (dt,
J= 1.0 Hz, J= 7.5 Hz, 1H, H13), 7.56 (dt, J = 1.5 Hz,
J= 8.0 Hz, 1H, H14), 7.66 (d, J = 8.8 Hz, 1H, H15), 7.77
(dd, J= 1.6 Hz, J= 8.2 Hz, 1H, H18), 7.85 (d, J = 1.6 Hz,
1H, H22), 7.89 (s, 1H, H9), 8.31 (d, J= 9.2 Hz, 1H, H3),
8.44 (d, J= 2.4 Hz, 1H, H6), 8.50 (dd, J= 2.4 Hz,
J= 9.2 Hz, 1H, H2).
13C NMR (151 MHz, CDCl3): d 101.67
(OCH2O), 108.0, 108.6, 121.0, 122.6, 122.7, 123.2, 124.7,
127.3, 130.3, 130.7, 131.3, 131.5, 132.7, 133.2, 135.5, 145.3,
148.4, 145.0, 150.7, 159.3 (Carom). IR (cm
1): t 3083, 2894,
1601, 1496, 1453, 1337, 1245, 1031, 888, 815. MSD 404.0
(M+).
Anal. Calcd. for C22H13ClN2O4: C, 65.28; H, 3.24; N, 6.92.
Found: C, 65.33; H, 3.19; N, 6.89.
4.1.3.11. 6-chloro-2-(phenanthren-3-yl)-4-phenylquinoline 42.
Yellow solid; yield 67%, mp 178–180 C, crystallized from
EtOH. 1H RMN (600 MHz, CDCl3): d 7.59–7.68 (m, 6H),
7.72–7.75 (m, 2H),7.82 (m, 2H) 7.91–7.92 (m, 2H), 8.05 (d,
J= 8.2 Hz, 1H), 8.08 (s, 1H, H-Het) 8.29 (d, J= 8.9 Hz,
1H), 8.46 (dd, J= 1.6 Hz; J= 8.2 Hz, 1H, H-Het), 8.91 (d,
J= 8.2 Hz ,1H, H-Het), 9.55 (d, J= 1.1 Hz, 1H, H-Het).
13C NMR (151 MHz, CDCl3) d 120.2, 122.1, 123.0, 124.6,
125.6, 126.6, 126.6, 126.8, 126.9, 128.0, 128.7, 128.8, 128.9,
129.2, 129.5, 129.5, 130.5, 130.6, 130.6, 131.8, 132.3, 132.3,
132.9, 137.1, 137.8, 147.4, 148.6, 157.1 (Carom). IR (cm
1): t
3005, 2956, 1591, 1544, 1486, 1361, 1153, 849, 748, 705.
MSD 416.0 (M+).
Anal. Calcd. for C29H18ClN: C, 83.75; H, 4.36; N, 3.37.
Found: C, 83.92; H, 4.39; N, 3.30.
4.1.3.12. 6-nitro-2-(phenanthren-3-yl)-4-phenylquinoline 43.
Yellow solid; yield 50%, mp 235–237 C, crystallized from
EtOH. 1H NMR (CDCl3): d 7.67 (s, 1H, HAAr), 7.70–7.88
(m, 8H, HAAr), 7.96 (d, J = 8.0 Hz, 1H, H-Het), 8.07 (d,
J = 8.0 Hz, 1H, H-Het), 8.22 (s, 1H, H-Het), 8.43–8.57 (m,
3H, HAAr), 8.90–8.93 (m, 2H, HAAr), 9.62 (s, 1H, H-Het).
13C NMR (CDCl3): d 120.9, 122.6, 122.9, 123.2, 124.9, 125.6,
126.5, 127.0, 128.6, 128.8, 129.2, 129.4, 129.5, 130.5, 131.8,
132.3, 133.4, 136.3, 137.0, 145.4, 151.4, 160.1 (Carom). IR
(cm1): t 3049, 3022, 1590, 1552, 1482, 1336, 1079, 838, 748,
695. MSD 427.1 (M+).
Anal. Calcd. for C29H18N2O2: C, 81.67; H, 4.25; N, 6.57.
Found: C, 81.62; H, 4.28; N, 6.54.
4.1.4. General procedure for compounds 44–45
A mixture of the corresponding aniline (0.50–0.52 mL, 5.5
mmoles), piperonal (0.79 g, 5.25 mmoles), 3-acetylindole or
acetophenone (0.87–0.66 g, 5.5 mmoles) with 0.15 mL of
TFA placed in a 50 mL round-bottomed flask was subjected
to MW irradiation at 400 W and 250 C. After completion
of the reaction (TLC) was proceed as described for 16–23.
4.1.4.1. 2-(benzo[d][1,3]dioxol-5-yl)-4-phenyl-6-(trifluo-
romethyl)quinoline 45. White solid; yield 49%, mp 115–
117 C, crystallized from EtOH. 1H RMN (600 MHz, CDCl3):
d 6.04 (s, 2H, OCH2O), 6.86 (d, J= 8.0 Hz, 1H, HAAr), 7.14
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J= 15.6 Hz, 1H, H-Het), 7.52 (t, J= 7.6 Hz, 2H, Ph), 7.59
(t, J= 7.2 Hz, 2H, Ph), 7.76 (d, J= 15.6 Hz, 1H, H-Het),
8.02 (m, 3H). 13C NMR (151 MHz, CDCl3): d 101.6 (OCH2O),
106.7, 108.7, 120.1, 125.2 (CF3), 128.4, 128.6, 129.4, 132.6,
138.4, 144.7, 148.4 (Carom), 149.93 (Carom-CF3). IR (cm
1): t
3036, 2922, 2785, 1660, 1590, 1503, 1450, 1253, 1018, 844,
777, 699, 598. MSD 392.0 (M+).
Anal. Calcd. for C23H14F3NO2: C, 70.23; H, 3.59; N, 3.56.
Found: C, 70.19; H, 3.62; N, 3.50.
4.2. In vitro activity against M. tuberculosis (Mtb)
4.2.1. Minimal inhibitory concentration (MIC)
The MIC of compound was determined by measuring bacterial
growth after 5 d in the presence of test compounds. Com-
pounds were prepared as 20-point two-fold serial dilutions in
DMSO and diluted into 7H9-Tw-OADC medium in 96-well
plates with a final DMSO concentration of 2%. The highest
concentration of compound was 200 mM where compounds
were soluble in DMSO at 10 mM. For compounds with limited
solubility, the highest concentration was 50X less than the
stock concentration e.g. 100 mM for 5 mM DMSO stock,
20 mM for 1 mM DMSO stock. Control compounds were pre-
pared as 10-point two-fold dilution series. Each plate included
assay controls for background (medium/DMSO only, no bac-
terial cells), zero growth (100 mM rifampicin) and maximum
growth (DMSO only), as well as a rifampicin dose response
curve. Plates were inoculated with M. tuberculosis and incu-
bated for 5 days: growth was measured by OD590 and fluores-
cence (Ex 560/Em 590) using a BioTekTM Synergy 4 plate
reader. Growth was calculated separately for OD590 and
RFU. To calculate the MIC, the dose response curve was plot-
ted as % growth and fitted to the Gompertz model using
GraphPad Prism 5. The MIC was defined as the minimum
concentration at which growth was completely inhibited and
was calculated from the inflection point of the fitted curve to
the lower asymptote (zero growth). In addition, dose response
curves were generated using the Levenberg-Marquardt algo-
rithm and the concentrations that resulted in 50% and 90%
inhibition of growth were determined (IC50 and IC90
respectively).
4.2.2. Minimal bactericidal concentration (MBC)
M. tuberculosis was grown aerobically to logarithmic phase
and inoculated into liquid medium containing four different
compound concentrations with a final maximum concentra-
tion of 2% DMSO. For compounds with an MIC (from
Task Group 1 assay), the concentrations selected were 10X
MIC, 5X MIC, 1X MIC, and 0.25X MIC. For compounds
with MIC > 20 mM, fixed concentrations of 200, 100, 20 and
5 mM were used (assuming solubility to 10 mM in DMSO).
Cultures were exposed to compounds for 21 days and cell via-
bility measured by enumerating colony forming units on agar
plates on day 0, 7, 14 and 21. MICs were calculated as the
average of the MIC derived from RFU and OD from Assay
Group 1.
MBC was defined as the minimum concentration required
to achieve a 2-log kill in 21 days. For compounds with >1-
log kill, an assessment of time- and/or concentration-dependence was determined from the kill kinetics. DMSO
was used as a positive control for growth.
4.2.3. Low-oxygen recovery assay (LORA)
Test compounds were prepared as 20-point two-fold serial
dilutions in DMSO and diluted into DTA medium in 96-well
plates with a final DMSO concentration of 2%. The highest
concentration of compound was 200 mM where compounds
were soluble in DMSO at 10 mM. For compounds with limited
solubility, the highest concentration was 50X less than the
stock concentration e.g. 100 mM for 5 mM DMSO stock,
20 mM for 1 mM DMSO stock. Control compounds were pre-
pared as 10-point two-fold serial dilutions in DMSO and
diluted into DTA medium in 96-well plates with a final DMSO
concentration of 2%.
M. tuberculosis constitutively expressing the luxABCDE
operon was inoculated into DTA medium in gas-
impermeable glass tubes and incubated for 18 days to generate
hypoxic conditions (Wayne model of hypoxia). At this point,
bacteria are in a non-replicating state (NRP stage 2) induced
by oxygen depletion.
4.2.4. Intracellular drug activity and cytotoxicity
Murine J774 macrophages were infected with a luminescent
strain of H37Rv (which constitutively expresses luxABCDE)
at a multiplicity of infection of 1. After 18 h, extracellular bac-
teria were removed by washing and compound was added.
Infected macrophages were incubated in the presence of com-
pound for 4 days at 1X and 10X MIC (as determined in aero-
bic culture in liquid medium from Task 1). For compounds
with MIC > 20 mM, fixed concentrations of 20 mM and
200 mM were used. Bacteria were harvested from macrophages
by lysis with 0.1% SDS, inoculated into growth media and
allowed to grow aerobically for 5 days, when the amount of
bacteria present was determined by luminescence. All assays
were conducted in triplicate; each assay included a positive
control (4 mM isoniazid) and a negative control (2% DMSO).
The intracellular activity was expressed as a log reduction of
M. tuberculosis using the formula:
Log RLU Day 4 Compound½   Log RLU Day 4 DMSO½ 
As a control for each assay, the inoculum was plated into
96-well plates, grown for 5 days and luminescence measured;
correlation of RLU and CFU was confirmed for each run
(data provided as excel spreadsheet). The baseline of infection
was determined by harvesting bacteria from macrophages at
day 0 before compound addition and plating for CFU determi-
nation in triplicate.
The cytotoxicity of compounds was determined by measur-
ing Vero cell viability growth after 2 d in the presence of test
compounds. Compounds were prepared as 10-point three-
fold serial dilutions in DMSO. Vero cells were cultured in
DMEM containing high glucose and GlutaMAXTM, 10%
FBS, and 1x of Penicillin-Streptomycin solution. Cells were
inoculated into assay plates and cultured for 24 h before com-
pound dilutions were added to a final DMSO concentration of
1%. The highest concentration of compound tested was
100 mM where compounds were soluble in DMSO at 10 mM.
For compounds with limited solubility, the highest concentra-
tion was 50X less than the stock concentration e.g. 100 mM for
944 G.C. Muscia et al.5 mM DMSO stock, 20 mM for 1 mM DMSO stock. Each
plate included staurosporine as a control.
4.3. QSAR study
The descriptors were from different classes such as autocorre-
lation descriptors [e.g., autocorrelation (charge)], chi indices
descriptors (e.g., chi chain), electrotopological state index
descriptors (e.g., atom type electrotopological state), BCUT
descriptors, constitutional descriptors (e.g., weight, ring
counts) and topological descriptors (e.g., Zagreb index, Wiener
numbers). The standard data reduction technique of ‘Principal
Component Analysis’ (PCA) was used to reduce the columns
of descriptors to the principal components that contain as
much of the original information as possible. The first three
PCA vectors were added to the study table containing the bin-
ary representation of the activity of the molecules (Todeschini
and Consonni, 2009).
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